PROLIFERATIVE ACTIVITY AND ADHESIVE PROPERTIES OF PCa WITH PHENOTYPE OF CANCER STEM CELLS
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-23-3-2021-g.9601Keywords:
cancer stem cells, intercellular adhesion, proliferative activity, prostate cancerAbstract
Aim: to investigate the proliferative activity and adhesive properties of prostate cancer (PCa) samples with the phenotype of cancer stem cells (CSC). Object and methods: the study was conducted on the clinical material of 120 patients with stage II-IV PCa who were treated at the National Cancer Institute, Ministry of Health of Ukraine during 2015–2017. The study of proliferation, adhesion, and CSC markers expression was performed on FFPE using immunohistochemical methods of mono- and double immunostaining. Analysis of functional interactions of proteins was performed using the resource STRING v.11.0. Statistical processing of the obtained results was performed using Statista 6.0 software. Results: we showed that the presence of CSC in the tumor tissue of PCa patients is associated with high proliferative activity of tumor cells and violation of their adhesive properties by reducing the expression of E-cadherin and increasing the level of N-cadherin. It was determined that high proliferative activity and violation of adhesive properties are features of low-differentiated PCa with the CSC phenotype in patients at late stages of the tumor process, category T3, with the presence of metastatic lesions of regional lymph nodes. We have established an association of the Ki-67 and N-cadherin expression with the Gleason index indicates the participation of these proteins in the formation of the PCa malignancy degree with the expression of CSC markers. Conclusions: thus, the presence of cells with the CSC phenotype against the background of high proliferative potential and violation of intercellular adhesion in PCa tissue is associated with an unfavorable course, which according to clinical and pathological indicators has a high malignancy degree.
References
Rawla P. Epidemiology of Prostate Cancer. World J Oncol 2019; 10 (2), 63–89.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2021; 71 (3): 209–49.
Cancer in Ukraine, 2019–2020. Incidence, mortality, activities of oncological service. Bull Nat Cancer Registry Ukr, № 22, Кyiv, 2020. 82 p
Stakhovskyi ЕO, Voylenko ОA, Vitruk UV, et al. Prostate cancer prophylaxis. Clin Oncol 2016; (1): 47–9 (in Russian).
Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012; 22 (3): 457–72.
Shackleton M, Quintana E, Fearon ER, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009; 138 (5): 822–29.
Eun K, Ham SW, Kim H. Cancer stem cell heterogeneity: origin and new perspectives on CSC targeting. BMB Rep 2017; 50 (3): 117–25.
Chekhun SV, Zadvorny TV, Tymovska YO, et al. СD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes. Exp Oncol 2015; 37 (1): 58–63.
Zhilchuk YuV, Sakalo VS, Grigorenko VN, et al. Expression of CD44 and CD24 in tumor tissue from patients with prostate cancer. Health of man 2016; 4 (59): 111–4 (in Ukrainian).
McClelland RA, Wilson D, Leake R, et al. A multicentre study into the reliability of steroid receptor immunocytochemical assay quantification. Eur J Cancer Clin Oncol 1991; 27 (6): 711–15.
Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci 2018; 25: 20. doi:10.1186/s12929–018–0426–4.
Afify SM, Seno M. Conversion of stem cells to cancer stem cells: Undercurrent of Cancer Initiation. Cancers 2019; 11(3): 345. doi:10.3390/cancers11030345.
Yang L, Shi P, Zhao G, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther 2020; 5 (1), 1–35.
Bae KM, Su Z, Frye C, et al. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 2010; 183 (5): 2045–53.
Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer 2013, 13 (10): 727–38.
Tomita K, Van Bokhoven A, van Leenders GJ, et al. Cadherin switching in human prostate cancer progression. Cancer Res 2000: 60 (13): 3650–54.
Matuszak EA, Kyprianou N. Androgen regulation of epithelial–mesenchymal transition in prostate tumorigenesis. Expert Rev Endocrinol Metab 2011; 6 (3): 469–82.
Gravdal K, Halvorsen OJ, Haukaas SA, et al. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res 2009; 69 (11): 4708–15.
